AstraZeneca Presents Results of Calquence (acalabrutinib) in P-III (ELEVATE-TN) Trial as 1L Treatment of Chronic Lymphocytic Leukaemia at ASCO 2022
- The P-III (ELEVATE-TN) trial evaluating Calquence as monothx. or in combination with obinutuzumab vs chlorambucil + obinutuzumab in a ratio (1:1:1) in 535 patients with CLL
- The results showed a PFS & OS benefit, 89% reduction in risk of disease progression or death in combination at a median follow-up of 58.2mos. & 79% as monothx; patients were alive (90% & 84% vs 82%) @5yrs., OS data are immature & the relative risk for death was 45%
- In the P-III (ASCEND) trial, Calquence showed a sustained PFS benefit @4yr., patients were alive (62%) @42mos. vs 19% with IdR/BR.3, median follow-up (46.5mos. vs 45.3mos.). The safety & tolerability in both trials were consistent with earlier findings with no new safety signals
Ref: AstraZeneca | Image: AstraZeneca
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.